Holen Sie sich die Stockscreener-App
54.30
0.88%
-0.48
Handel nachbörslich:
54.35
0.05
+0.09%
Überblick
Nachrichten
Preisverlauf
Optionskette
Warum fällt NVO?
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$54.78
Offen:
$54.33
24-Stunden-Volumen:
14.03M
Relative Volume:
0.96
Marktkapitalisierung:
$184.08B
Einnahmen:
$45.44B
Nettoeinkommen (Verlust:
$16.18B
KGV:
14.94
EPS:
3.634
Netto-Cashflow:
$9.21B
1W Leistung:
+6.68%
1M Leistung:
-15.57%
6M Leistung:
-35.16%
1J Leistung:
-60.02%
1-Tages-Spanne:
$53.83
$54.63
1-Wochen-Bereich:
$49.87
$55.48
52-Wochen-Spanne:
$45.05
$139.74
Novo Nordisk Adr Stock (NVO) Company Profile
Vergleichen Sie NVO mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
NVO
Novo Nordisk Adr
|
54.30 | 238.83B | 45.44B | 16.18B | 9.21B | 3.634 |
|
LLY
Lilly Eli Co
|
705.44 | 625.77B | 53.26B | 13.80B | -50.20M | 15.30 |
|
JNJ
Johnson Johnson
|
178.84 | 424.47B | 90.62B | 22.66B | 18.18B | 9.35 |
|
ABBV
Abbvie Inc
|
209.15 | 364.92B | 58.33B | 3.73B | 18.24B | 2.10 |
|
NVS
Novartis Ag Adr
|
127.25 | 240.07B | 53.40B | 13.68B | 16.89B | 6.9231 |
|
MRK
Merck Co Inc
|
84.66 | 210.36B | 63.43B | 16.42B | 14.72B | 6.49 |
Novo Nordisk Adr Stock (NVO) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-08-13 | Hochstufung | BNP Paribas Exane | Underperform → Neutral |
| 2025-08-05 | Herabstufung | UBS | Buy → Neutral |
| 2025-07-31 | Herabstufung | HSBC Securities | Buy → Hold |
| 2025-07-30 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2025-04-17 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2025-03-13 | Hochstufung | Kepler | Hold → Buy |
| 2025-03-03 | Herabstufung | Stifel | Buy → Hold |
| 2025-02-12 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2025-01-06 | Hochstufung | Bernstein | Underperform → Mkt Perform |
| 2024-05-30 | Eingeleitet | Goldman | Buy |
| 2024-04-12 | Eingeleitet | BMO Capital Markets | Outperform |
| 2024-01-23 | Eingeleitet | Morgan Stanley | Overweight |
| 2024-01-16 | Fortgesetzt | UBS | Neutral |
| 2023-12-01 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2023-10-02 | Eingeleitet | Argus | Buy |
| 2023-07-14 | Eingeleitet | HSBC Securities | Buy |
| 2022-07-15 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2022-06-28 | Herabstufung | UBS | Neutral → Sell |
| 2022-06-27 | Hochstufung | Exane BNP Paribas | Underperform → Neutral |
| 2022-06-07 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2022-05-31 | Hochstufung | Guggenheim | Neutral → Buy |
| 2022-04-25 | Hochstufung | Cowen | Market Perform → Outperform |
| 2022-04-12 | Hochstufung | Morgan Stanley | Underweight → Equal-Weight |
| 2022-03-16 | Hochstufung | Deutsche Bank | Hold → Buy |
| 2022-01-25 | Herabstufung | Liberum | Hold → Sell |
| 2021-12-20 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2021-12-17 | Herabstufung | Deutsche Bank | Buy → Hold |
| 2021-01-20 | Herabstufung | Credit Suisse | Outperform → Neutral |
| 2021-01-15 | Eingeleitet | Deutsche Bank | Buy |
| 2020-09-29 | Eingeleitet | Berenberg | Hold |
| 2020-07-06 | Herabstufung | BofA Securities | Buy → Neutral |
| 2020-05-11 | Herabstufung | UBS | Buy → Neutral |
| 2020-05-04 | Eingeleitet | Cowen | Market Perform |
| 2020-03-16 | Hochstufung | BofA/Merrill | Neutral → Buy |
| 2020-01-03 | Herabstufung | Guggenheim | Buy → Neutral |
| 2019-11-18 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2019-09-17 | Hochstufung | Citigroup | Neutral → Buy |
| 2019-08-30 | Herabstufung | Jefferies | Hold → Underperform |
| 2019-06-20 | Herabstufung | Deutsche Bank | Buy → Hold |
| 2019-06-11 | Hochstufung | Barclays | Underweight → Equal Weight |
| 2019-04-29 | Hochstufung | Credit Suisse | Neutral → Outperform |
| 2019-01-29 | Eingeleitet | Exane BNP Paribas | Outperform |
| 2018-12-11 | Fortgesetzt | Jefferies | Hold |
| 2018-10-09 | Eingeleitet | Guggenheim | Buy |
| 2017-12-29 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2017-12-06 | Hochstufung | BofA/Merrill | Neutral → Buy |
| 2017-12-01 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2017-09-25 | Herabstufung | Exane BNP Paribas | Outperform → Neutral |
| 2017-09-06 | Hochstufung | BofA/Merrill | Underperform → Neutral |
Alle ansehen
Novo Nordisk Adr Aktie (NVO) Neueste Nachrichten
HIMS & HERS HEALTH SHAREHOLDER ALERT: CLAIMSFILER REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuits Against Hims & Hers Health, Inc. - GlobeNewswire Inc.
HIMS INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Hims & Hers Health, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - GlobeNewswire Inc.
INVESTOR DEADLINE NEXT WEEK: Robbins Geller Rudman & Dowd LLP Announces that Hims & Hers Health, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - GlobeNewswire Inc.
Using data models to predict Novo Nordisk A s (b Shares) Adrhedged stock movementBuy Signal & Weekly Stock Performance Updates - Newser
Reversal indicators forming on Novo Nordisk A s (b Shares) Adrhedged stockJuly 2025 Action & Daily Growth Stock Investment Tips - Newser
Can momentum traders help lift Novo Nordisk A s (b Shares) Adrhedged2025 Stock Rankings & Long-Term Safe Investment Plans - Newser
Is Novo Nordisk A s (b Shares) Adrhedged showing signs of accumulationJuly 2025 Institutional & Low Risk Entry Point Tips - Newser
Is Novo Nordisk A s (b Shares) Adrhedged still worth holding after the dipTrade Risk Assessment & Consistent Growth Equity Picks - Newser
Does Novo Nordisk A s (b Shares) Adrhedged fit your quant trading modelMarket Trend Summary & Detailed Earnings Play Alerts - Newser
Is Novo Nordisk A s (b Shares) Adrhedged stock ready for a breakoutMarket Risk Report & Verified Short-Term Plans - Newser
What moving averages say about Novo Nordisk A s (b Shares) Adrhedged2025 Top Gainers & Community Verified Swing Trade Signals - Newser
What’s next for Novo Nordisk A s (b Shares) Adrhedged stock priceEarnings Recap Report & Expert Approved Momentum Trade Ideas - Newser
Earnings visualization tools for Novo Nordisk A s (b Shares) AdrhedgedChart Signals & Precise Entry and Exit Recommendations - Newser
Using portfolio simulators with Novo Nordisk A s (b Shares) Adrhedged includedJuly 2025 Catalysts & Verified Momentum Stock Ideas - Newser
Novo Nordisk shares rise 1.58% premarket after board member Christina Law's ADR purchase. - AInvest
Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons - The Manila Times
Novo Nordisk Board Member Christina Law Buys $0.8 Million in ADRs - AInvest
Novo Nordisk Board Member Christina Law Purchases ADRs Worth DKK 0.8 Million - MarketScreener
Technical signs of recovery in Novo Nordisk A s (b Shares) AdrhedgedPortfolio Risk Report & Real-Time Stock Entry Alerts - Newser
Novo Nordisk A s (b Shares) Adrhedged stock prediction for this weekJuly 2025 Final Week & Pattern Based Trade Signal System - Newser
Glenn Jorgensen @Glennjdk: "𝐖𝐞 𝐡𝐚𝐝 𝐦𝐨𝐫𝐞 𝐍𝐨𝐯𝐨 𝐍𝐨𝐫𝐝𝐢𝐬𝐤..." - eToro
Using data filters to optimize entry into Novo Nordisk A s (b Shares) Adrhedged2025 Top Decliners & Technical Entry and Exit Alerts - Newser
How to monitor Novo Nordisk A s (b Shares) Adrhedged with trend dashboards2025 Winners & Losers & Detailed Earnings Play Strategies - Newser
AI Trend Models Suggest Bounce for Novo Nordisk A s (b Shares) AdrhedgedMarket Weekly Review & AI Driven Price Predictions - Newser
Is Novo Nordisk A s (b Shares) Adrhedged trending in predictive chart modelsWeekly Investment Recap & Fast Gain Stock Trading Tips - Newser
Applying sector rotation models to Novo Nordisk A s (b Shares) AdrhedgedIndex Update & Fast Exit/Entry Strategy Plans - Newser
How to forecast Novo Nordisk A s (b Shares) Adrhedged trends using time seriesMarket Sentiment Report & Long-Term Safe Investment Plans - Newser
Is Novo Nordisk A s (b Shares) Adrhedged Stock a Smart Buy in 2025 Investment Analysis Inside - Newser
Chart based exit strategy for Novo Nordisk A s (b Shares) AdrhedgedJuly 2025 EndofMonth & Free Growth Oriented Trading Recommendations - Newser
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Novo Nordisk A/S of Class Action Lawsuit and Upcoming Deadlines - GlobeNewswire Inc.
Full technical analysis of Novo Nordisk A s (b Shares) Adrhedged stockNew Guidance & High Conviction Investment Ideas - Newser
Why Novo Nordisk A s (b Shares) Adrhedged stock attracts strong analyst attentionDollar Strength & Pattern Based Trade Signal System - Newser
Price action breakdown for Novo Nordisk A s (b Shares) AdrhedgedWeekly Trade Recap & Free High Return Stock Watch Alerts - Newser
Finanzdaten der Novo Nordisk Adr-Aktie (NVO)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.30%
0.32%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):